Watching science cross that invisible line between theory and therapy is something magnetic. Eradivir just locked in $10M in private financing to do exactly that, turn immune chemistry into something that can end a viral infection faster than your coffee cools. This isn’t a biotech chasing buzzwords. It’s a clinical-stage force out of West Lafayette, Indiana, spun from Purdue University research, led by CEO Martin Low and Dr. Philip S. Low, two names that carry real scientific weight, not just LinkedIn shine.
Martin Low’s got that rare mix, Kellogg MBA precision with the patience of a biochemist who’s seen molecules misbehave before they perform. Dr. Philip S. Low is biotech royalty: Presidential Scholar for Drug Discovery, Ralph C. Corley Distinguished Professor of Chemistry, and founder of Endocyte, the company Novartis scooped up for $2.1B. When these two link up, it’s not a startup pitch, it’s a masterclass in execution.
Their play is BAiT, the Bispecific Antigenic immuno-Therapy platform. Think small molecules acting like guided missiles, tethering immune cells to infected or diseased targets. The lead drug, EV25, doesn’t just slow down influenza, it wipes out detectable virus within 24 hours in preclinical models. Phase 2a trials are wrapped, and a 375-patient Phase 2b is locked for fall 2025. Not bad for a 10-person crew waging war on viruses from a Midwest lab with more bite than gloss.
Investors see it too. This $10M round, powered by returning backers, brings total funding north of $32M. Names like NSF, BARDA DRIVe, and Open Philanthropy don’t just write checks, they place bets on what’s next. Their continued backing signals this platform isn’t luck, it’s leverage.
Inside the walls, the chemistry’s lethal and the leadership’s stacked. Dr. Madduri Srinivasarao leads discovery like a conductor of chaos turned maestro. Dr. Jeffery Nielsen runs R&D with an eye for precision that borders on obsession. Mary Niedrauer drives drug development with cool control, and Dr. Raymond Schinazi, yes, the mind behind sofosbuvir, the backbone of Gilead’s hepatitis cure, anchors the board.
This round isn’t just runway, it’s validation. If EV25 clears its next trial, we’re talking a single-dose antiviral effective even days post-infection, a shot at reshaping a $14.2B influenzatherapy market growing at 7% CAGR.
